KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $881.0 million.

  • Alnylam Pharmaceuticals' Operating Expenses rose 5247.62% to $881.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 2901.73%. This contributed to the annual value of $2.4 billion for FY2024, which is 1490.95% up from last year.
  • Alnylam Pharmaceuticals' Operating Expenses amounted to $881.0 million in Q3 2025, which was up 5247.62% from $789.9 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Operating Expenses ranged from a high of $881.0 million in Q3 2025 and a low of $360.0 million during Q1 2022
  • In the last 5 years, Alnylam Pharmaceuticals' Operating Expenses had a median value of $536.7 million in 2023 and averaged $534.6 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Operating Expenses crashed by 105.24% in 2022, and later surged by 5247.62% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Operating Expenses stood at $453.1 million in 2021, then grew by 15.57% to $523.6 million in 2022, then grew by 6.2% to $556.1 million in 2023, then grew by 25.57% to $698.3 million in 2024, then grew by 26.17% to $881.0 million in 2025.
  • Its Operating Expenses stands at $881.0 million for Q3 2025, versus $789.9 million for Q2 2025 and $576.1 million for Q1 2025.